期刊文献+

口服替吉奥在晚期消化道肿瘤维持化疗安全性观察与疗效分析 被引量:6

Safety Observation and Curative Effect Analysis of Maintenance Chemotherapy with Oral S-1 in Advanced Gastrointestinal Cancer
下载PDF
导出
摘要 目的:观察口服替吉奥作为晚期消化道肿瘤维持化学治疗(化疗)的耐受性和近期疗效。方法:对30例有可测量病灶晚期消化道肿瘤采用标准剂量替吉奥口服,观察其不良反应和近期疗效。结果:白细胞减少发生率30.0%,恶心呕吐发生率23.3%,不良反应发生率低;30例中,CR1例,PR9例,客观有效率(RR)33.3%,疾病控制率(DCR)为53.3%。结论:口服替吉奥在晚期消化道肿瘤维持化疗耐受性好,安全、方便,近期疗效确切。 Objective:To investigate drug tolerance and short term effect of advanced gastrointestinal cancer treated by maintenance chemotherapy with oral S-1.Methods:A total of 30 patients with advanced gastrointestinal cancer who had measurable tumor lesions were treated with full dose of oral S-1.The adverse reactions were carefully observed and recent curative effect was evaluated in time.Results:In safety analysis,30%of the cases was leucopenia and 23.3%of the cases were nausea and vomiting.The incidence of adverse reactions is low.Of all patients,the complete response(CR) was 1 case,partial response(PR) was in 9 cases,and the objective response rate(PR) and disease control rate(DCR) were 33.3%and 53.3%,respectively.Conclusion:The oral S-1 is a well-tolerated,safe,convenient and highly effective maintenance chemotherapeutic regimen in advanced gastrointestinal cancer.
出处 《中国医药导刊》 2013年第11期1834-1835,共2页 Chinese Journal of Medicinal Guide
关键词 替吉奥 晚期消化道肿瘤 化疗 毒性 S-1 Advanced gastrointestinal cancer Chemotherapy Toxicity
  • 相关文献

参考文献12

  • 1Kamaogar F,Dores GM,Anderson WF.Patteras of cancer incidence,mortality,andprevalence across five continents:defining priorities to reduce c-icer disparities indifferent geograjrfiie regions of the world[J].J Clin oncol,2001 ;24.:2137-2150.
  • 2Sakuramoto S,Sasako M,Yamaguchi T,et al.Adjuvant chemotherapy for gastriccanca" with s-l,an oral fluoropyrimidine[J].N Eng! J Med,2007;357:1810-1820.
  • 3Shirasaka T,Shimamoto Y,Ohshirno H,et al.Develop-ment of a novel form of anoral 5-fluorouracil derivatives-1 )directed to the potentiation of the tumor selectivecyto- toxicity of 5-fluorouracil by two biochemical modulators[J]-AnticancerDrugs,1996;7(5):548-557.
  • 4Dasio RB.Clinical implications of dihydropyrimidine dehy-drogenase inhibition[J].Oncoloy(Williston f-rk), 1999; 13(Suppl 3):17-21.
  • 5KoizumiW,Kurihara M,Nakano S,et ai.Phase H study of S-l a novel oral derivativeof 5-fhuorouraciL in advanced gastric cancer[J].0ncology,2000;58(3): 191 -197.
  • 6Matsumot H,Hirai T,Hirabayashi Y,et ai.A phase I / II study of docetaxel/TS-J with radiation for esopha-geal cancer patients-stepl[J].Gan To KagakuRyoho,2006;33( 13):2021 -2026.
  • 7黄镜,王向玲,周一,周爱萍,陶云霞,王金万.替吉奥为基础的化疗在消化道肿瘤中安全性的观察和分析[J].癌症进展,2011,9(6):707-710. 被引量:32
  • 8刘莉,郑盈,张智勇,丁昌利,陆震宇.替吉奥单药口服治疗老年晚期胃癌的临床观察[J].实用癌症杂志,2011,26(3):294-296. 被引量:65
  • 9赖邻宁,杜敏,祝艳华,杜华昆,马小南.替吉奥联合伊立替康与替吉奥单药治疗晚期结肠癌的临床对照研究[J].中国肿瘤临床与康复,2012,19(1):42-45. 被引量:19
  • 10Landry J,Tepper JE, Wood WC,et al,Patterns of failure following curative resectionof gastrice cancer[J].Int J Radiat Oncol Biol Phys,1990;191:1357-1362.

二级参考文献34

  • 1Parkin DM,Bray F,Ferlay J,et al.Global cancer statistics,2002[J].CA Cancer J Clin,2005,55(2):74.
  • 2Miller A B,Hoogstraten B,Staquet M,et al.Reporting results of cancer treatment[J].Cancer,1981,47(1):207.
  • 3Alberts SR,Cervantes A,VANDE Velde CJ,et al.Gastric cancer:epidemiology,pathology and treatment[J].Ann Oncol,2003,14(suppl 2):S31.
  • 4Sato A,Ito T,Tomita T.Chemotherapy of gastric cancer-a review of clinical trials in Japan 2002[J].Gan To Kaggku Ryobo,2002,29(9):1522.
  • 5Koizumi W.S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer.(SPIRITS trial):a phase Ⅲ trial[J].Lancet Oncol,2008,9(3):215.
  • 6Boku N.Chemotherapy for metastatic disease:review from JCOG trials[J].International Journal of Clinical Oncology,2008,13(3):196.
  • 7白坂哲彦 佃守犬山 夫他新规.经口抗癌剂TS-1(S-1).癌症化学疗法,2001,:855-864.
  • 8Ajani J A,Rodriguez W,Bodoky G,et al.Multicenter phase Ⅲ comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study:the FLAGS trial[J].J Clin Oncol,2010,28 (9):1547-1553.
  • 9Koizumi W,Tanabe S,Saigenji K,et al.PhaseⅠ/Ⅱ study of S-1 combined with cisplatin in patients with advanced gastric cancer[J].Br J Cancer,2003,89 (12):2207-2212.
  • 10Shirasaka T,Shimamoto Y,Ohshimo H,et al.Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators[J].Anticancer Drugs,1996,7 (5):548-557.

共引文献107

同被引文献45

引证文献6

二级引证文献57

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部